Non-prescription gel goes on topically to counter erectile dysfunction and is an OTC alternative to Viagra.
VICTORIA, BC / ACCESSWIRE / January 23, 2024 / As an OTC alternative to Viagra and Cialis, Eroxon was US FDA-approved on June 13, 2023, and is available from both storefront and online pharmacies, including Canada Pharmacy and others in Canada, which can offer a lower price on Eroxon.
![Canada Pharmacy Logo](https://www.accesswire.com/imagelibrary/0902dd16-7ae5-497b-8e17-ca0807e2a193/827471/f34806d292be044b3fbdde4f6314.jpg)
Eroxon, which comes in single-dose tubes of gel, is also expected to be a comparatively affordable erectile dysfunction treatment. Eroxon received approval in the European Union as a Class 2B medical device in April 2021.
Eroxon is a topical gel with a different mechanism of action compared to these other ED treatment meds. It works with a combination of solvents that evaporate quickly to promote a cooling-to-warming effect, resulting in more nitric oxide relaxing smooth muscle tissue. This enhances blood flow, and it is claimed that Eroxon will take effect within 10 minutes of application.
US residents are increasingly having prescriptions filled in Canada because of the lower costs for prescription medications. This also applies to OTC products, including Eroxon, as it is becoming more available in America.
About the Company
Canada Pharmacy is a Canadian online pharmacy among those recommended for Americans who shop at a pharmacy in Canada to save money on medications. It can source medications in a way that allows for the best prices on prescription drugs from Canada. All orders require a prescription and are dispensed by a licensed pharmacist, in the same way as it would be with any pharmacy in America. Pay less when you order drugs online from Canada.
Contact Canada Pharmacy:
https://www.canadapharmacy.com
Toll Free: 1-800-891-0844
Contact Information
Marketing Team
Marketing Team
marketing@canadapharmacy.com
1-800-891-0844
SOURCE: Canada Pharmacy
View the original press release on newswire.com.